Presentation Information
[3CTBP-09-KL]Anticancer Activity of Novel Arctic Lichen Extracts in Triple-Negative Breast Cancer via Mitochondrial-Dependent Apoptosis
○Yunji Kang1, Boram Son1, Bowon Jung2, Seulah Lee2 (1. Kookmin Univ. (Korea), 2. KyungHee Univ. (Korea))
Keywords:
TNBC,Breast cancer,Anticancer,Arctic linchen,Apoptosis
[Purpose]
Triple-negative breast cancer (TNBC) is characterized by the absence of estrogen, progesterone, and HER2 receptors, which significantly limits treatment options compared to other breast cancer types that respond to hormonal or targeted therapies. TNBC carries the highest risk of recurrence within the first five years following diagnosis. While the five-year survival rate for hormone receptor-positive (HR+) breast cancer exceeds 90%, TNBC shows a markedly lower rate, ranging from 61% to 77%. Furthermore, various studies report that approximately 30–40% of TNBC patients experience recurrence or metastasis within five years of diagnosis, underscoring the urgent need for research into novel therapeutic agents.
[Method]
In this study, we analyzed the anticancer efficacy of compounds extracted from Arctic lichens and propose these novel extracts—which have no prior reports of anticancer activity—as potential materials for next-generation therapies.
[Results]
Experimental results revealed that among the tested compounds, atranol(8) exhibited the most potent inhibitory effect on cell proliferation, with IC50 values ranging from 99μM to 130μM. Morphological observations showed that while the normal control cells maintained a distinct, elongated, and clear structure, the group treated with the compound underwent rapid morphological collapse over a 48-hour period. Additionally, Western blot analysis confirmed that this compound induces the activation of caspase-3.
[Consideration]
These findings suggest that the compound triggers the mitochondrial-dependent apoptotic pathway, leading to the programmed death of TNBC cells.
[Conclusion]
Consequently, this study demonstrates that constituents derived from Arctic lichens hold significant potential as natural lead compounds for anticancer drug development.
Triple-negative breast cancer (TNBC) is characterized by the absence of estrogen, progesterone, and HER2 receptors, which significantly limits treatment options compared to other breast cancer types that respond to hormonal or targeted therapies. TNBC carries the highest risk of recurrence within the first five years following diagnosis. While the five-year survival rate for hormone receptor-positive (HR+) breast cancer exceeds 90%, TNBC shows a markedly lower rate, ranging from 61% to 77%. Furthermore, various studies report that approximately 30–40% of TNBC patients experience recurrence or metastasis within five years of diagnosis, underscoring the urgent need for research into novel therapeutic agents.
[Method]
In this study, we analyzed the anticancer efficacy of compounds extracted from Arctic lichens and propose these novel extracts—which have no prior reports of anticancer activity—as potential materials for next-generation therapies.
[Results]
Experimental results revealed that among the tested compounds, atranol(8) exhibited the most potent inhibitory effect on cell proliferation, with IC50 values ranging from 99μM to 130μM. Morphological observations showed that while the normal control cells maintained a distinct, elongated, and clear structure, the group treated with the compound underwent rapid morphological collapse over a 48-hour period. Additionally, Western blot analysis confirmed that this compound induces the activation of caspase-3.
[Consideration]
These findings suggest that the compound triggers the mitochondrial-dependent apoptotic pathway, leading to the programmed death of TNBC cells.
[Conclusion]
Consequently, this study demonstrates that constituents derived from Arctic lichens hold significant potential as natural lead compounds for anticancer drug development.
Comment
To browse or post comments, you must log in.Log in